Old Web
English
Sign In
Acemap
>
authorDetail
>
Xen Ianopulos
Xen Ianopulos
Cirmtuzumab
Cancer research
Mantle cell lymphoma
Ibrutinib
Medicine
4
Papers
11
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
2020
Blood
Hun Ju Lee
Michael Y. Choi
Tanya Siddiqi
William G. Wierda
Jacqueline C. Barrientos
Nicole Lamanna
Alec Goldenberg
Iris Isufi
Joseph Tuscano
Suki Subbiah
Jean L. Koff
Lori A. Leslie
Gina G. Chung
Elizabeth Weihe
Xen Ianopulos
James B. Breitmeyer
Frank J. Hsu
Michael Wang
Catriona Jamieson
Thomas J. Kipps
Show All
Source
Cite
Save
Citations (4)
Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
2020
Journal of Clinical Oncology
Hun Ju Lee
Michael Y. Choi
Tanya Siddiqi
William G. Wierda
Jacqueline C. Barrientos
Nicole Lamanna
Alec Goldenberg
Iris Isufi
Joseph Tuscano
Suki Subbiah
Elizabeth Weihe
Xen Ianopulos
James Bradley Breitmeyer
Frank J. Hsu
Michael Wang
Catriona Jamieson
Thomas J. Kipps
Show All
Source
Cite
Save
Citations (1)
Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.
2019
Journal of Clinical Oncology
Michael Y. Choi
William G. Wierda
Hun Ju Lee
Dimitrios Tzachanis
Xen Ianopulos
Deborah Jezior
James Bradley Breitmeyer
Catriona Jamieson
Thomas J. Kipps
Show All
Source
Cite
Save
Citations (5)
1